Physician profile
Kevin M King
NPI 1386636538
$904.14
in general payments reported to CMS, 2019-2025
11 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.45 · 2020: $106 · 2021: $47.45 · 2022: $90.08 · 2023: $220 · 2024: $264 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $237.35 | 2019-2025 | Tryptyr, Rocklatan, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $196.91 | 2020-2024 | Tecnis Iol, Tecnis Simplicity |
| Apellis Pharmaceuticals, INC. | $120.00 | 2023 | Syfovre |
| Rxsight INC | $119.34 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $46.36 | 2025 | |
| Abbvie INC. | $46.29 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $45.75 | 2023-2024 | Vyzulta, Xiidra, Miebo |
| Ocular Therapeutix, INC. | $29.00 | 2023-2024 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $27.12 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $20.46 | 2023 | |
| Harrow Eye, LLC | $15.56 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.